Pediatric Hypertension: Diagnosis and Management
Begin screening all children for hypertension at age 3 years and above, define hypertension as BP ≥95th percentile for age/sex/height, and initiate lifestyle modifications immediately with pharmacologic therapy (ACE inhibitor, ARB, long-acting calcium channel blocker, or thiazide diuretic) reserved for persistent stage 1 hypertension after 6-12 months of lifestyle changes, stage 2 hypertension, symptomatic hypertension, or presence of left ventricular hypertrophy. 1
Diagnostic Approach
Blood Pressure Measurement and Classification
Screen asymptomatic children starting at 3 years of age at every medical encounter 2. Hypertension is defined as:
- Stage 1: BP between 95th percentile and 95th percentile + 12 mmHg
- Stage 2: BP >95th percentile + 12 mmHg
- For adolescents ≥13 years: use adult thresholds of ≥130/80 mmHg 1
Use validated devices with proper cuff sizing—incorrect cuff size is a common pitfall that leads to misdiagnosis 3.
Confirmation and Evaluation
Ambulatory blood pressure monitoring (ABPM) is strongly recommended to confirm the diagnosis before initiating treatment, particularly for stage 1 hypertension persisting 6-12 months 2. ABPM also identifies masked hypertension and absence of nocturnal dipping, both critical prognostic markers for cardiovascular morbidity 2.
Obtain a comprehensive history focusing on:
- Perinatal history
- Nutritional and physical activity patterns
- Psychosocial factors and adverse childhood experiences 3
- Family history of hypertension
- Symptoms suggesting secondary causes 1
Distinguishing Primary from Secondary Hypertension
Secondary causes predominate in younger children, while primary (essential) hypertension becomes more common after age 5-6 years, especially with obesity or positive family history 2. Renal parenchymal and renovascular etiologies are the most common secondary causes 2.
For suspected renovascular hypertension:
- Doppler renal ultrasonography as initial noninvasive screening in normal-weight children ≥8 years 1
- CTA or MRA for definitive imaging if renal artery stenosis suspected 1
Cardiac Target Organ Damage Assessment
Do NOT perform routine electrocardiography—it is not recommended 1. Instead:
Perform echocardiography at the time of considering pharmacologic treatment to assess for left ventricular hypertrophy (LVH), which is defined as:
- LV mass >51 g/m^2.7 for children >8 years (both sexes), OR
- LV mass >115 g/BSA for boys or >95 g/BSA for girls 1, 4
Repeat echocardiography at 6-12 month intervals if:
- Persistent hypertension despite treatment
- Concentric LV hypertrophy present
- Reduced LV ejection fraction 1
For patients without initial LVH, consider yearly echocardiography in those with stage 2 hypertension, secondary hypertension, or incompletely treated chronic stage 1 hypertension 1.
Routine microalbuminuria testing is NOT recommended for primary hypertension 1.
Management Strategy
Treatment Goals
Target BP <90th percentile for age, or <130/80 mmHg in adolescents ≥13 years, whichever is lower 1, 4. This straightforward target is based on evidence showing hypertensive target organ damage can appear at BP levels between 90th-95th percentiles 4.
Lifestyle Modifications (First-Line for All)
At diagnosis, immediately advise:
- DASH diet (Dietary Approaches to Stop Hypertension)
- Moderate to vigorous physical activity 3-5 days per week, 30-60 minutes per session 1
- Weight management if overweight/obese 2
- Limit salt consumption 5
Emerging effective approaches include circadian nutrition, stress management, psychological counseling for behavior modification, and interdisciplinary team approaches 5. These lifestyle interventions can be as effective as pharmacologic therapy when compliance is achieved 5.
Pharmacologic Therapy Indications
Initiate antihypertensive medications when:
- Stage 1 hypertension persists after 6-12 months of lifestyle modifications 2
- Stage 2 hypertension without clearly modifiable factor (e.g., obesity) 1
- Symptomatic hypertension 4
- LVH present on echocardiography 1
- Any stage hypertension with diabetes mellitus or CKD 1, 4
First-Line Pharmacologic Agents
Choose from four drug classes with pediatric efficacy and safety data:
- ACE inhibitors
- Angiotensin receptor blockers (ARBs)
- Long-acting calcium channel blockers
- Thiazide diuretics 1, 4
Special populations requiring specific agents:
- CKD with hypertension and proteinuria: ACE inhibitor or ARB (strong recommendation) 1
- Diabetes mellitus with hypertension: ACE inhibitor or ARB 4
This represents a major advance since 2004, as legislative initiatives resulted in pediatric studies for most newer antihypertensive medications, providing robust efficacy and safety data 4.
Monitoring Treatment Effectiveness
Use ABPM to assess treatment response, especially when clinic/home BP measurements suggest insufficient response 1. This is particularly critical in secondary hypertension to identify masked hypertension and monitor nocturnal dipping 2.
Special Populations
Chronic Kidney Disease
- Evaluate for hypertension at every medical encounter 1
- Treat to lower 24-hour mean arterial pressure <50th percentile by ABPM 1
- Screen for proteinuria—if present, use ACE inhibitor or ARB 1
- Perform ABPM at least yearly even if office BP appears controlled, to screen for masked hypertension 1
Diabetes (Type 1 or Type 2)
- Evaluate for hypertension at every medical encounter 1
- Treat if BP ≥95th percentile or >130/80 mmHg in adolescents ≥13 years 1
Acute Severe Hypertension with Life-Threatening Symptoms
Initiate immediate treatment with short-acting IV antihypertensive medication (sodium nitroprusside or labetalol preferred), with initial goal of controlled reduction to 95th percentile 2.
Critical Pitfalls to Avoid
- Incorrect cuff sizing leading to false readings 3
- Relying on single office measurements without ABPM confirmation 2
- Performing ECG instead of echocardiography for cardiac assessment 1
- Delaying pharmacotherapy in stage 2 hypertension or when LVH is present 1
- Missing masked hypertension in CKD patients by not performing yearly ABPM 1
- Failing to screen for proteinuria in CKD patients 1